{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:45Z","timestamp":1792191945486,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate smooth muscle contraction is central in treatment of voiding symptoms in benign prostatic hyperplasia (BPH). Tissues from transurethral resection of the prostate (TURP) and radical prostatectomy (RP) for prostate cancer are widely used to study contractions. However, findings are limited by traumatization in TURP, and uncertain relationship to BPH in RP tissues. This study aims to examine contractions of laser-enucleated tissues. Tissues from holmium\/thulium laser enucleation (HoLEP\/ThuLEP) and TURP were contracted by KCl, noradrenaline and electric field stimulation (EFS) in an organ bath. Contractions were compared to RP tissues in previous studies. KCl-induced contractions averaged 2.5 mN, 0.7 mN and 3.3 mN in tissues from HoLEP\/ThuLEP, TURP and RP, with non-responsive tissues included (2.4% HoLEP\/ThuLEP, 37% TURP). Maximum EFS-induced contractions (E<jats:sub>max<\/jats:sub>) averaged 47% of KCl in HoLEP\/ThuLEP tissues, 27% in TURP tissues, and 68\u2013235% in 21 previous studies with RP tissues. E<jats:sub>max<\/jats:sub> values for noradrenaline averaged 99.7% in HoLEP\/ThuLEP tissues, 56% in TURP tissues, and ranged from 92 to 260% in RP tissues. Preoperative \u03b1<jats:sub>1<\/jats:sub>-blocker treatment reduced EFS- and noradrenaline-induced contractions, and increased EC<jats:sub>50<\/jats:sub> values for noradrenaline in laser-enucleated, catheterized patients, but not in patients without catheterization. Also, the ex vivo application of \u03b1<jats:sub>1<\/jats:sub>-blockers increased the EC<jats:sub>50<\/jats:sub> values for noradrenaline and reduced E<jats:sub>max<\/jats:sub> for EFS. Laser-enucleated tissues allow investigation of prostate smooth muscle contraction in medication-refractory voiding symptoms. Different impacts of preoperative \u03b1<jats:sub>1<\/jats:sub>-blocker treatment on ex vivo contractility in tissues from patients with and without catheterization point to clinically relevant heterogeneity of patients undergoing surgery for BPH.<\/jats:p>","DOI":"10.1038\/s41598-025-88884-7","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:48:16Z","timestamp":1739198896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative \u03b11-blocker treatment in patients with and without catheterization"],"prefix":"10.1038","volume":"15","author":[{"given":"Patrick","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Schierholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwafemi E.","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Waidelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"Suppl 9","key":"88884_CR1","first-page":"S3","volume":"6","author":"H Lepor","year":"2004","unstructured":"Lepor, H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev. Urol. 6(Suppl 9), S3\u2013S10 (2004).","journal-title":"Rev. Urol."},{"key":"88884_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/164_2023_678","author":"M Hennenberg","year":"2023","unstructured":"Hennenberg, M. & Michel, M. C. Adrenoceptors in the Lower Urinary Tract. Handb. Exp. Pharmacol. https:\/\/doi.org\/10.1007\/164_2023_678 (2023).","journal-title":"Handb. Exp. Pharmacol."},{"key":"88884_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas, S. et al. Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. Eur. Urol. 84, 207\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008 (2023).","journal-title":"Eur. Urol."},{"key":"88884_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0140-6736(20)31287-3","volume":"396","author":"G Magistro","year":"2020","unstructured":"Magistro, G. & Stief, C. G. Surgery for benign prostatic obstruction. Lancet 396, 5\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(20)31287-3 (2020).","journal-title":"Lancet"},{"key":"88884_CR5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/nau.25242","volume":"42","author":"S Hu","year":"2023","unstructured":"Hu, S. et al. Selective inhibition of neurogenic, but not agonist-induced contractions by phospholipase A(2) inhibitors points to presynaptic phospholipase A(2) functions in contractile neurotransmission to human prostate smooth muscle. Neurourol. Urodyn. 42, 1522\u20131531. https:\/\/doi.org\/10.1002\/nau.25242 (2023).","journal-title":"Neurourol. Urodyn."},{"key":"88884_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00210-023-02664-6","volume":"397","author":"S Hu","year":"2024","unstructured":"Hu, S. et al. Organ-specific off-target effects of Pim\/ZIP kinase inhibitors suggest lack of contractile Pim kinase activity in prostate, bladder, and vascular smooth muscle. Naunyn. Schmiedebergs Arch. Pharmacol. 397, 1219\u20131231. https:\/\/doi.org\/10.1007\/s00210-023-02664-6 (2024).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"88884_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.666047","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang, R. et al. Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate. Front. Pharmacol. 12, 666047. https:\/\/doi.org\/10.3389\/fphar.2021.666047 (2021).","journal-title":"Front. Pharmacol."},{"key":"88884_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/nu14234943","author":"R Huang","year":"2022","unstructured":"Huang, R. et al. Inhibition of alpha(1)-adrenergic, non-adrenergic and neurogenic human prostate smooth muscle contraction and of stromal cell growth by the isoflavones genistein and daidzein. Nutrients https:\/\/doi.org\/10.3390\/nu14234943 (2022).","journal-title":"Nutrients"},{"key":"88884_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pros.24248","volume":"82","author":"R Huang","year":"2022","unstructured":"Huang, R. et al. Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983. Prostate 82, 59\u201377. https:\/\/doi.org\/10.1002\/pros.24248 (2022).","journal-title":"Prostate"},{"key":"88884_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115148","volume":"202","author":"R Huang","year":"2022","unstructured":"Huang, R. et al. Antagonism of alpha(1)-adrenoceptors by beta(3)-adrenergic agonists: Structure-function relations of different agonists in prostate smooth muscle contraction. Biochem. Pharmacol. 202, 115148. https:\/\/doi.org\/10.1016\/j.bcp.2022.115148 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"88884_CR11","doi-asserted-by":"publisher","first-page":"1105427","DOI":"10.3389\/fphar.2023.1105427","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003. Front. Pharmacol. 14, 1105427. https:\/\/doi.org\/10.3389\/fphar.2023.1105427 (2023).","journal-title":"Front. Pharmacol."},{"key":"88884_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00210-020-02044-4","volume":"394","author":"A Spek","year":"2021","unstructured":"Spek, A. et al. Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists. Naunyn Schmiedebergs Arch. Pharmacol. 394, 1113\u20131131. https:\/\/doi.org\/10.1007\/s00210-020-02044-4 (2021).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"88884_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119771","volume":"281","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas, A. et al. Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction. Life Sci. 281, 119771. https:\/\/doi.org\/10.1016\/j.lfs.2021.119771 (2021).","journal-title":"Life Sci."},{"key":"88884_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pros.24114","volume":"81","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas, A. et al. Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?. Prostate 81, 377\u2013389. https:\/\/doi.org\/10.1002\/pros.24114 (2021).","journal-title":"Prostate"},{"key":"88884_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.884057","volume":"13","author":"A Tamalunas","year":"2022","unstructured":"Tamalunas, A. et al. Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule galpha(q\/11) inhibitor, YM-254890. Front. Physiol. 13, 884057. https:\/\/doi.org\/10.3389\/fphys.2022.884057 (2022).","journal-title":"Front. Physiol."},{"key":"88884_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120931","volume":"308","author":"A Tamalunas","year":"2022","unstructured":"Tamalunas, A. et al. Permixon(R), hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells. Life Sci. 308, 120931. https:\/\/doi.org\/10.1016\/j.lfs.2022.120931 (2022).","journal-title":"Life Sci."},{"key":"88884_CR17","doi-asserted-by":"publisher","first-page":"F47","DOI":"10.1152\/ajprenal.00125.2017","volume":"314","author":"A Herlemann","year":"2018","unstructured":"Herlemann, A. et al. Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. Am. J. Physiol. Renal. Physiol. 314, F47\u2013F57. https:\/\/doi.org\/10.1152\/ajprenal.00125.2017 (2018).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"88884_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00210-019-01797-x","volume":"393","author":"B Li","year":"2020","unstructured":"Li, B. et al. The STK16 inhibitor STK16-IN-1 inhibits non-adrenergic and non-neurogenic smooth muscle contractions in the human prostate and the human male detrusor. Naunyn Schmiedebergs Arch. Pharmacol. 393, 829\u2013842. https:\/\/doi.org\/10.1007\/s00210-019-01797-x (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"88884_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/pros.23998","volume":"80","author":"B Li","year":"2020","unstructured":"Li, B. et al. Inhibition of neurogenic and thromboxane A2 -induced human prostate smooth muscle contraction by the integrin alpha2beta1 inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. Prostate 80, 831\u2013849. https:\/\/doi.org\/10.1002\/pros.23998 (2020).","journal-title":"Prostate"},{"key":"88884_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.172985","volume":"873","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by alpha1-blockers. Eur. J. Pharmacol. 873, 172985. https:\/\/doi.org\/10.1016\/j.ejphar.2020.172985 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"88884_CR21","doi-asserted-by":"publisher","first-page":"4748312","DOI":"10.1155\/2019\/4748312","volume":"2019","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Ghrelin aggravates prostate enlargement in rats with testosterone-induced benign prostatic hyperplasia, stromal cell proliferation, and smooth muscle contraction in human prostate tissues. Oxid. Med. Cell Longev. 2019, 4748312. https:\/\/doi.org\/10.1155\/2019\/4748312 (2019).","journal-title":"Oxid. Med. Cell Longev."},{"key":"88884_CR22","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1074\/jbc.RA119.007958","volume":"294","author":"Q Yu","year":"2019","unstructured":"Yu, Q. et al. A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. J. Biol. Chem. 294, 12231\u201312249. https:\/\/doi.org\/10.1074\/jbc.RA119.007958 (2019).","journal-title":"J. Biol. Chem."},{"key":"88884_CR23","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bph.14201","volume":"175","author":"Q Yu","year":"2018","unstructured":"Yu, Q. et al. Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. Br. J. Pharmacol. 175, 2077\u20132096. https:\/\/doi.org\/10.1111\/bph.14201 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"88884_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejphar.2018.04.022","volume":"831","author":"Q Yu","year":"2018","unstructured":"Yu, Q. et al. Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2\/3, CMPD101. Eur. J. Pharmacol. 831, 9\u201319. https:\/\/doi.org\/10.1016\/j.ejphar.2018.04.022 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"88884_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3389\/fphys.2018.00734","volume":"9","author":"M Hennenberg","year":"2018","unstructured":"Hennenberg, M. et al. Inhibition of prostate smooth muscle contraction by inhibitors of polo-like kinases. Front. Physiol. 9, 734. https:\/\/doi.org\/10.3389\/fphys.2018.00734 (2018).","journal-title":"Front. Physiol."},{"key":"88884_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.urology.2023.02.014","volume":"175","author":"A Tamalunas","year":"2023","unstructured":"Tamalunas, A. et al. Efficacy, efficiency, and safety of en-bloc vs three-lobe enucleation of the prostate: A propensity score-matched analysis. Urology 175, 48\u201355. https:\/\/doi.org\/10.1016\/j.urology.2023.02.014 (2023).","journal-title":"Urology"},{"key":"88884_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00210-022-02218-2","volume":"395","author":"R Huang","year":"2022","unstructured":"Huang, R. et al. Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729. Naunyn Schmiedebergs Arch. Pharmacol. 395, 471\u2013485. https:\/\/doi.org\/10.1007\/s00210-022-02218-2 (2022).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"88884_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/mol.119.118927","volume":"97","author":"MC Michel","year":"2020","unstructured":"Michel, M. C., Murphy, T. J. & Motulsky, H. J. New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. Mol. Pharmacol. 97, 49\u201360. https:\/\/doi.org\/10.1124\/mol.119.118927 (2020).","journal-title":"Mol. Pharmacol."},{"issue":"Suppl 2","key":"88884_CR29","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel, M. C. & Vrydag, W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 147(Suppl 2), S88-119. https:\/\/doi.org\/10.1038\/sj.bjp.0706619 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"88884_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diff.2017.07.005","volume":"96","author":"DW Strand","year":"2017","unstructured":"Strand, D. W., Costa, D. N., Francis, F., Ricke, W. A. & Roehrborn, C. G. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96, 49\u201361. https:\/\/doi.org\/10.1016\/j.diff.2017.07.005 (2017).","journal-title":"Differentiation"},{"key":"88884_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109102","volume":"9","author":"TM Bauman","year":"2014","unstructured":"Bauman, T. M. et al. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One 9, e109102. https:\/\/doi.org\/10.1371\/journal.pone.0109102 (2014).","journal-title":"PLoS One"},{"key":"88884_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2147\/IJGM.S395705","volume":"16","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. The symptoms of benign prostatic hyperplasia patients with stromal-dominated hyperplasia nodules may be associated with prostate fibrosis. Int. J. Gen. Med. 16, 1181\u20131191. https:\/\/doi.org\/10.2147\/IJGM.S395705 (2023).","journal-title":"Int. J. Gen. Med."},{"key":"88884_CR33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrurol.2013.149","volume":"10","author":"JA Rodriguez-Nieves","year":"2013","unstructured":"Rodriguez-Nieves, J. A. & Macoska, J. A. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat. Rev. Urol. 10, 546\u2013550. https:\/\/doi.org\/10.1038\/nrurol.2013.149 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"88884_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-022-04979-3","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis. 13, 533. https:\/\/doi.org\/10.1038\/s41419-022-04979-3 (2022).","journal-title":"Cell Death Dis."},{"key":"88884_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/pros.23293","volume":"77","author":"M Hennenberg","year":"2017","unstructured":"Hennenberg, M. et al. Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace alpha1 -adrenergic tension in the human prostate. Prostate 77, 697\u2013707. https:\/\/doi.org\/10.1002\/pros.23293 (2017).","journal-title":"Prostate"},{"key":"88884_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/pcan.2016.33","volume":"19","author":"C Gilfrich","year":"2016","unstructured":"Gilfrich, C. et al. Morbidity and mortality after surgery for lower urinary tract symptoms: A study of 95 577 cases from a nationwide German health insurance database. Prostate Cancer Prostatic Dis 19, 406\u2013411. https:\/\/doi.org\/10.1038\/pcan.2016.33 (2016).","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"88884_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.urology.2023.05.028","volume":"179","author":"IC Weinstein","year":"2023","unstructured":"Weinstein, I. C. et al. Adoption and outcomes of holmium laser enucleation of the prostate in the United States. Urology 179, 106\u2013111. https:\/\/doi.org\/10.1016\/j.urology.2023.05.028 (2023).","journal-title":"Urology"},{"key":"88884_CR38","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00345-023-04509-6","volume":"41","author":"A Behr","year":"2023","unstructured":"Behr, A. et al. Comparison of surgical procedures for benign prostatic hyperplasia of medium-volume prostates: Evaluation of the causes of rehospitalization from the French National Hospital Database (PMSI-MCO). World J. Urol. 41, 2481\u20132488. https:\/\/doi.org\/10.1007\/s00345-023-04509-6 (2023).","journal-title":"World J. Urol."},{"key":"88884_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.urology.2021.04.004","volume":"154","author":"G Magistro","year":"2021","unstructured":"Magistro, G. et al. Enucleation vs. Resection: A Matched-pair Analysis of TURP, HoLEP and Bipolar TUEP in Medium-sized Prostates. Urology 154, 221\u2013226. https:\/\/doi.org\/10.1016\/j.urology.2021.04.004 (2021).","journal-title":"Urology"},{"key":"88884_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/luts.12366","volume":"13","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas, A. et al. The clinical value of holmium laser enucleation of the prostate in octogenarians. Low Urin. Tract Symptoms 13, 279\u2013285. https:\/\/doi.org\/10.1111\/luts.12366 (2021).","journal-title":"Low Urin. Tract Symptoms"},{"key":"88884_CR41","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00345-020-03468-6","volume":"39","author":"G Bozzini","year":"2021","unstructured":"Bozzini, G. et al. A prospective multicenter randomized comparison between holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP). World J Urol 39, 2375\u20132382. https:\/\/doi.org\/10.1007\/s00345-020-03468-6 (2021).","journal-title":"World J Urol"},{"key":"88884_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00345-021-03805-3","volume":"40","author":"S Hein","year":"2022","unstructured":"Hein, S. et al. Thermal effects of thulium: YAG laser treatment of the prostate-an in vitro study. World J. Urol. 40, 161\u2013167. https:\/\/doi.org\/10.1007\/s00345-021-03805-3 (2022).","journal-title":"World J. Urol."},{"key":"88884_CR43","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00345-022-04041-z","volume":"40","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz, M. et al. Temperature assessment study of ex vivo holmium laser enucleation of the prostate model. World J Urol 40, 1867\u20131872. https:\/\/doi.org\/10.1007\/s00345-022-04041-z (2022).","journal-title":"World J Urol"},{"key":"88884_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000528849","volume":"107","author":"M Yilmaz","year":"2023","unstructured":"Yilmaz, M. et al. In vivo temperature assessment during holmium laser enucleation of the prostate. Urol Int 107, 363\u2013369. https:\/\/doi.org\/10.1159\/000528849 (2023).","journal-title":"Urol Int"},{"key":"88884_CR45","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1089\/end.2017.0679","volume":"31","author":"AH Aldoukhi","year":"2017","unstructured":"Aldoukhi, A. H., Ghani, K. R., Hall, T. L. & Roberts, W. W. Thermal response to high-power holmium laser lithotripsy. J. Endourol. 31, 1308\u20131312. https:\/\/doi.org\/10.1089\/end.2017.0679 (2017).","journal-title":"J. Endourol."},{"key":"88884_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/end.2018.0485","volume":"33","author":"AD Maxwell","year":"2019","unstructured":"Maxwell, A. D. et al. Simulation of laser lithotripsy-induced heating in the urinary tract. J. Endourol 33, 113\u2013119. https:\/\/doi.org\/10.1089\/end.2018.0485 (2019).","journal-title":"J. Endourol"},{"key":"88884_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ajur.2021.11.002","volume":"10","author":"C Breitling","year":"2023","unstructured":"Breitling, C., Nenning, H. & Rassler, J. Necrosis zone depth after bipolar plasma vaporization and resection in the human prostate. Asian J Urol. 10, 144\u2013150. https:\/\/doi.org\/10.1016\/j.ajur.2021.11.002 (2023).","journal-title":"Asian J Urol."},{"key":"88884_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/end.1995.9.151","volume":"9","author":"PJ Gilling","year":"1995","unstructured":"Gilling, P. J., Cass, C. B., Malcolm, A. R. & Fraundorfer, M. R. Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. J. Endourol. 9, 151\u2013153. https:\/\/doi.org\/10.1089\/end.1995.9.151 (1995).","journal-title":"J. Endourol."},{"key":"88884_CR49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.eururo.2020.06.004","volume":"78","author":"MJ Drake","year":"2020","unstructured":"Drake, M. J. et al. Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: A noninferiority randomised controlled trial of urodynamics in 26 hospitals. Eur. Urol. 78, 701\u2013710. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.004 (2020).","journal-title":"Eur. Urol."},{"key":"88884_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.euf.2019.04.006","volume":"5","author":"AL Lewis","year":"2019","unstructured":"Lewis, A. L. et al. Clinical and patient-reported outcome measures in men referred for consideration of surgery to treat lower urinary tract symptoms: baseline results and diagnostic findings of the urodynamics for prostate surgery trial; randomised evaluation of assessment methods (UPSTREAM). Eur. Urol. Focus 5, 340\u2013350. https:\/\/doi.org\/10.1016\/j.euf.2019.04.006 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"88884_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel, M. C. et al. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol. Rev. 75, 554\u2013674. https:\/\/doi.org\/10.1124\/pharmrev.121.000523 (2023).","journal-title":"Pharmacol. Rev."},{"key":"88884_CR52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s13063-015-1087-1","volume":"16","author":"K Bailey","year":"2015","unstructured":"Bailey, K. et al. Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men: study protocol for a randomised controlled trial. Trials 16, 567. https:\/\/doi.org\/10.1186\/s13063-015-1087-1 (2015).","journal-title":"Trials"},{"key":"88884_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s13063-017-2206-y","volume":"18","author":"GJ Young","year":"2017","unstructured":"Young, G. J. et al. Statistical analysis plan for the urodynamics for prostate surgery trial; randomised evaluation of assessment methods (UPSTREAM). Trials 18, 455. https:\/\/doi.org\/10.1186\/s13063-017-2206-y (2017).","journal-title":"Trials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88884-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:48:22Z","timestamp":1739198902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88884-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88884-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4985"}}